{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:53:49Z","timestamp":1774968829243,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.biopha.2008.09.011","type":"journal-article","created":{"date-parts":[[2008,10,24]],"date-time":"2008-10-24T07:29:18Z","timestamp":1224833358000},"page":"337-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The metabolic syndrome, an epidemic among HIV-infected patients on HAART"],"prefix":"10.1016","volume":"63","author":[{"given":"Dj.","family":"Jevtovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Dragovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Salemovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ranin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Djurkovi\u0107-Djakovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. A","key":"10.1016\/j.biopha.2008.09.011_bib1","first-page":"S157","article-title":"Altered natural history of AIDS-related opportunistic infections in the era of potent combination anti-retroviral therapy","volume":"12","author":"Jacobson","year":"1998","journal-title":"AIDS"},{"issue":"Suppl. A","key":"10.1016\/j.biopha.2008.09.011_bib2","first-page":"S25","article-title":"Immune reconstitution in HIV infection","volume":"13","author":"Gea-Banacloche","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2008.09.011_bib3","first-page":"621","article-title":"A syndrome of lipodystrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome","volume":"19","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2008.09.011_bib4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2008.09.011_bib5","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"Carr","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2008.09.011_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy. Prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"issue":"RR-17","key":"10.1016\/j.biopha.2008.09.011_bib7","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"CDC","year":"1992","journal-title":"MMWR"},{"key":"10.1016\/j.biopha.2008.09.011_bib8","first-page":"2486","article-title":"(Adult Treatment Panel III)","volume":"285","author":"Executive Summary of the Third Report of the National Cholesterol Education Program [NCEP] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2008.09.011_bib9","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factors categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2008.09.011_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00002030-199902040-00008","article-title":"Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group","volume":"13","author":"Pakker","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2008.09.011_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopha.2005.07.006","article-title":"The dissociation between virological and immunological responses to HAART","volume":"59","author":"Jevtovi\u0107","year":"2005","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.biopha.2008.09.011_bib12","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(98)12291-2","article-title":"Drug-resistance genotyping in HIV-1 therapy: the VIRADEPT randomised controlled trial","volume":"353","author":"Durant","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2008.09.011_bib13","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipodystrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor related lipodystrophy syndrome","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2008.09.011_bib14","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1086\/317477","article-title":"Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999","volume":"31","author":"Thi\u00e9baut","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.biopha.2008.09.011_bib15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2008.09.011_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00126334-200107010-00004","article-title":"Stavudine versus zidovudine and the development of lipodystrophy","volume":"27","author":"Bogner","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2008.09.011_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1310\/BRE5-448N-WUPU-JWVL","article-title":"Lipodystrophy in 685 HIV-1 treated patients: influence of antiretroviral treatment and immunovirological response","volume":"2","author":"Baufassa","year":"2001","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.biopha.2008.09.011_bib18","unstructured":"Miller JE, Emery S, French M, Baker D, Cooper D. The Australian prevalence survey of lipodystrophy syndrome. In: Program and abstracts of the seventh conference of retroviruses and opportunistic infections, San Francisco; January 2008 [Abst. 201]."},{"key":"10.1016\/j.biopha.2008.09.011_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00126334-200303010-00018","article-title":"Hepatitis C virus in patients with HIV infection and lipodystrophy","volume":"32","author":"Rodriguez-Guardado","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2008.09.011_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1468-1293.2006.00416.x","article-title":"Lipid abnormalities in HIV\/hepatitis C virus-coinfected patients","volume":"7","author":"Bedimo","year":"2006","journal-title":"HIV Med"},{"key":"10.1016\/j.biopha.2008.09.011_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/QAI.0b013e318042d5fe","article-title":"Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens","volume":"45","author":"Anastos","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2008.09.011_bib22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brikman","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2008.09.011_bib23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0022-3565(24)29565-3","article-title":"Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice","volume":"297","author":"Gaou","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopha.2008.09.011_bib24","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-1 infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biopha.2008.09.011_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1468-1293.2007.00470.x","article-title":"Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy","volume":"8","author":"Riddler","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.biopha.2008.09.011_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/QAI.0b013e31804216cf","article-title":"Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, non-nucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy","volume":"54","author":"Shlay","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.biopha.2008.09.011_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2217\/17469600.2.1.83","article-title":"Cardiovascular risk and choice of HIV drug regimen","volume":"2","author":"Sabin","year":"2008","journal-title":"Future HIV Ther"},{"key":"10.1016\/j.biopha.2008.09.011_bib28","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"The Data Collection on Adverse Events of Anti-HIV Drugs [DAD] Study Group","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332208003296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332208003296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:42:36Z","timestamp":1760092956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332208003296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0753332208003296"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2008.09.011","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The metabolic syndrome, an epidemic among HIV-infected patients on HAART","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2008.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}